{"entity":{"id":"attraction-2","kind":"trial","name":"ATTRACTION-2","aka":[],"tldr":"ATTRACTION-2 was the first randomised trial to show that an immunotherapy drug, nivolumab, helps people with heavily pretreated stomach cancer live longer than placebo, and it made nivolumab a late-line option in East Asia before any Western approval.","summary":"ATTRACTION-2 was a double-blind phase 3 trial run by Ono Pharmaceutical across Japan, South Korea and Taiwan in patients with unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer that had progressed after two or more chemotherapy regimens. Patients were randomised two to one to nivolumab or placebo; PD-L1 expression was not required and was analysed afterwards.\n\nNivolumab prolonged overall survival compared with placebo, the primary endpoint, and the benefit held in longer follow-up. The result led to approval of nivolumab for previously treated gastric cancer in Japan in September 2017, the first checkpoint inhibitor approval in this disease, and it seeded the first-line chemo-immunotherapy trials that followed (ATTRACTION-4 and CheckMate 649).","status":"positive","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT02267343","url":"https://clinicaltrials.gov/study/NCT02267343"}],"tags":["subtype-trials"],"related":[],"cancers":["gastric-pdl1-high","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["kang-yoon-koo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02267343","phase":"3","setting":"Advanced gastric or gastro-oesophageal junction cancer in Japan, South Korea and Taiwan after at least two prior chemotherapy regimens: nivolumab or placebo, irrespective of PD-L1 expression","sponsor":"Ono Pharmaceutical","result":"Nivolumab improved overall survival over placebo in heavily pretreated advanced gastric cancer; approved in Japan in September 2017.","yearReported":2017,"enrolled":493,"outcomes":[]},"route":"/trials/attraction-2/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"gastric-pdl1-high","kind":"cancer","name":"PD-L1-high gastric cancer","route":"/cancers/gastric-pdl1-high/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"person":[{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/"}]}}